Moexipril Hydrochloride Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 7.5 mg, 15 mg
Reference Brands: Univasc (USA)
Category:
Heart Disorder
Moexipril Hydrochloride is available in Tablets
and strengths such as 7.5 mg, 15 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Moexipril Hydrochloride is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Moexipril Hydrochloride can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Moexipril is an angiotensin-converting enzyme (ACE) inhibitor that has been used in the management of hypertension and congestive heart failure. It may be administered as monotherapy or in combination with other antihypertensive agents, including diuretics, to achieve optimal blood pressure control. By reducing systemic vascular resistance, moexipril helps improve blood flow and decreases the workload on the heart.
The primary mechanism of action of moexipril involves inhibition of the angiotensin-converting enzyme, which prevents the conversion of angiotensin I into angiotensin II. Since angiotensin II is a potent vasoconstrictor, its reduction leads to relaxation of blood vessels and effective lowering of blood pressure. This mechanism plays a key role in controlling hypertension within the vasculature and improving cardiovascular hemodynamics.
In addition to its antihypertensive effects, moexipril has demonstrated cardioprotective properties. Preclinical studies have shown that administration of moexipril prior to myocardial infarction resulted in a reduction in infarct size, indicating protective effects on heart tissue. These benefits are attributed to a combination of angiotensin II inhibition and increased bradykinin activity. Elevated bradykinin levels stimulate the production of prostaglandin E2 and nitric oxide, leading to vasodilation and antiproliferative effects, which further support cardiovascular protection.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing